Eloxx Pharmaceuticals Recruits VP of Human Resources

GattiHR Assists Eloxx Pharmaceuticals in Recruiting Key Member of Their Leadership Team

GattiHR is pleased to announce Rose Villandry has joined Eloxx Pharmaceuticals as VP of Human Resources.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel. (www.eloxxpharma.com).

Rose was most recently Vice President of Human Resources at Flexion Therapeutics.

“Eloxx Pharmaceuticals gained a true asset. Rose’s extensive background in HR will undoubtably strengthen their leadership team,” said Kevin Coughlin, Managing Director at GattiHR.